ArticleJournal of pharmacy & bioallied sciences
Formulation and Evaluation of Levofloxacin and Betamethasone Ophthalmic Emulgel.
Article in Journal of pharmacy & bioallied sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Innovative Hydrogel Formulation Combining Phycocyanin and Probiotic for Enhancing Skin Regeneration and Accelerated Wound Healing: A Preclinical Investigation in Wistar Rats.Probiotics and antimicrobial proteins · 2026Article
- Emulsion and Emulgel-Based Ophthalmic Drug Delivery Systems.Pharmaceutics · 2025Review
- A multifunctional hydrogel system with synergistic effects againstMaterials today. Bio · 2025Article
- Development and Evaluation of the Acaricidal Activity of Xantan Gum-Based Hydrogel and Polymeric Nanoparticles ContainingGels (Basel, Switzerland) · 2024Article
- Review
- Pulmonary Targeting of Levofloxacin Using Microsphere-Based Dry Powder Inhalation.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Electrospun Nanofiber Composite for Levofloxacin in Ocular Drug Delivery.Pharmaceutical nanotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDrug delivery to ocular tissues is challenging due to rapid removal of instilled drug due to low resident time in ocular tissues. The aim of the study was to formulate an ophthalmic emulgel that delivers two drugs (betamethasone sodium phosphate [BSP] and levofloxacin). The new combination will allow the simultaneous administration and extended release of the two drugs which potentially improve resident time in ocular tissues, patient compliance, and adherence to treatment. MATERIALS AND
methodsFormulations containing different gelling agents at different concentrations were prepared to choose the optimum combination regarding physical properties and release. The emulgel formulations F1, F2, F3, and F4 were made using gelling agent 1% and 2% xanthan gum, 1% carbopole 934, and 2% methyl cellulose, respectively. F5 was formulated using 2% methyl cellulose with double the amount of poloxamer 188 as emulsifying agent. All the formulations were examined regarding their physical appearance, pH, viscosity, drug content, and
resultsThe results demonstrated that F5 was the optimum formulation having a proper physical characteristics and release profile of both drugs, 96% and 90% for BSP and levofloxacin, respectively, compared to other formulations and commercial eye drops.
conclusionSimultaneous and extended release of the two drugs was achieved using one formulation of emulgel. The ability to deliver hydrophilic and hydrophobic drug through the same formulation without the need to use two drops will improve patient compliance and hence patient adherence to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.